Board of Directors


Peter Hammond – Chairman

Peter Hammond

Peter is a managing director of Exto Partners. He has successfully invested in and co-founded more than a dozen companies. In the process he played key leadership roles in the successful commercialisation of many innovative products that are now selling throughout the global market.

With extensive experience in venture capital, strategy and corporate finance, Peter has advised biotechnology, financial services, manufacturing, consumer services and technology companies in Australia and the USA. Peter has assisted companies through a wide range of growth paths and transitions, including early stage financing, the bringing of new products to global markets, and large-scale mergers.

Peter is a member of the Institute of Chartered Accountants and has a B.Bus. from the University of Technology Sydney. He is currently a Director of Exto Partners, Ondek, Sensear, EnVie Fitness, Airtasker, and WhiteSky Labs.

Dr Barry Marshall – Executive Director

Barry Marshall

Professor Marshall is a world authority on Helicobacter pylori. He is the co-discoverer that H. pylori plays a major causative role in peptic ulcer diseases and co-recipient of the 2005 Nobel Prize for Physiology or Medicine as well as numerous other prestigious awards (including the 1995 Lasker Award). Professor Marshall was elected as a Fellow of the Royal Society in 1999 and the US National Academy of Sciences in 2008. He is one of the most esteemed and pre-eminent biomedical scientists in the world today. His discovery has revolutionised the management of peptic ulcer disease, resulting in a cure for peptic ulcers. Related research into a diagnostic test for H. pylori led to a patentable technology and the formation of TriMed Distributors Pty Ltd, a successful private company.

Dr Marshall is the founder of Ondek®. He is also a Clinical Professor at the University of Western Australia and a practising specialist gastroenterologist.

Dr Jenny Harry – Chief Executive Officer

Jenny Harry

Jenny Harry has 20 years experience in executive management, securing global partnerships, commercialising technologies and raising capital. In her previous role, as CEO and Managing Director of Tyrian Diagnostics (ASX:TDX), Jenny transformed the company from an R&D business to a diagnostics company, and oversaw development of the company’s first diagnostic products through to commercialisation and early revenue generation. Jenny’s corporate experience extends to leading companies in the biotechnology and biopharmaceutical sectors with expertise in creating effective organisation structures, building high performing teams, strategic planning, and negotiating with multi-national corporations on the development and commercialisation of products.

Jenny received a PhD in developmental biology from Macquarie University, Sydney, and is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors. In addition to her role as Managing Director at Ondek®, Dr Harry is a non-executive director on several boards, including Chair of QUT Enterprise Holdings Pty Ltd and a non-executive director on the board of ASX-listed Neuren Pharmaceuticals.

Lars Molinder – Non Executive Director

Lars Molinder is currently Senior Adviser to Carnegie Investment Bank in Sweden. He has over 25 years of financial sector experience working solely with companies in the healthcare sector. Lars has been the Head of Medicine and Biotechnology at the Swedish Industrial Development Fund (Industrifonden) and made over 40 investments in early stage companies ranging from medical technology and diagnostics to pharmaceuticals and biotechnology. Prior to joining Carnegie Investment Bank, Lars was the Nordic Head of Healthcare Sector and European co-Head of Healthcare Banking at Alfred Berg and ABN AMRO. Selected recent deals include: advising IPOs of Recipharm, Academedia, Humana, Attendo, Capio, Wilson Therapeutics, Alligator Biosciences, Oncopeptides, Bone Support and BioArctic, all noted on the main list of Nasdaq Stockholm Stock Exchange. Lars has a M.Sc. in Engineering.